Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene

References

• Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D. Epidemiology, treatment and costs of osteoporosis in Germany – the BoneEVA Study. Osteoporos Int 2007;18:77–84
   PubMed Web of Science ®Google Scholar
• Pfeilschifter J. 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diabetes 2006;114:611–22
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003–8
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–22.
   PubMed Web of Science ®Google Scholar
• Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J 2007;100:1214–18
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008;23:1435–41
   PubMed Web of Science ®Google Scholar
• Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;122(2 Suppl):S3–13.
   PubMed Web of Science ®Google Scholar
• Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607–12
   PubMed Web of Science ®Google Scholar
• Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303–10
   PubMed Web of Science ®Google Scholar
• Hoer A, Seidlitz C, Gothe H, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 2009;3:25–30
   PubMed Web of Science ®Google Scholar
• Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010;73:156–66
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023–31
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
   PubMed Web of Science ®Google Scholar
• Bartl R, Gotte S, Hadji P, Hammerschmidt T. Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment. Dtsch Med Wochenschr 2006;131:1257–62
   PubMed Web of Science ®Google Scholar
• Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914–21
   PubMed Web of Science ®Google Scholar
• Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2000;(2):CD000011
   Google Scholar
• Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf 2005;28:721–30
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Ziller V, Gottschalk M, Hadji P. The use of raloxifene in the prevention and treatment of postmenopausal osteoporosis. J Menopause 2004;11:30–5
   Google Scholar
• Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–61
   PubMed Web of Science ®Google Scholar
• Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009;9:51–60
   PubMed Web of Science ®Google Scholar
• Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 2000;60:379–411
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–37
   PubMed Web of Science ®Google Scholar
• Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209–16
   PubMed Web of Science ®Google Scholar
• Ringe JD, Christodoulakos GE, Mellstrom D, et al. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin 2007;23:2677–87
   PubMed Web of Science ®Google Scholar
• Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20:431–6
   PubMed Web of Science ®Google Scholar
• Ziller V, Zimmermann SP, Kalder M, et al. Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 2010;26:675–81
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44–7
   PubMed Web of Science ®Google Scholar
• Sabate E. Adherence to long-term therapies: evidence for action. WHO Adherence to Long Term Therapies Project, 2003
   Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67–74
   PubMed Web of Science ®Google Scholar
• Pasion EG, Sivananthan SK, Kung AW, et al. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab 2007;25:105–13
   PubMed Web of Science ®Google Scholar
• Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26:245–56
   PubMed Web of Science ®Google Scholar
• Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007;82:1493–501
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Lincoln TM, Wilhelm K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 2007;96:232–45
   PubMed Web of Science ®Google Scholar